{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:27:46Z","timestamp":1762324066153},"reference-count":38,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2000,2,1]]},"abstract":"<jats:p> PURPOSE: To identify predictive factors for efficacy and safety in advanced breast cancer (ABC) patients treated in the French compassionate-use docetaxel program. <\/jats:p><jats:p> PATIENTS AND METHODS: A total of 825 ABC patients treated with docetaxel (100 mg\/m<jats:sup>2<\/jats:sup> every 3 weeks) were source-reviewed and analyzed for prognostic factors associated with overall response rate (ORR), time to treatment failure (TTF), overall survival (OS), febrile neutropenia, mucositis, and severe fluid retention syndrome by univariate and multivariate analysis. <\/jats:p><jats:p> RESULTS: The ORR was 22.9% (95% confidence interval, 20.2% to 26.2%). The median TTF and OS were 4.0 and 9.8 months, respectively. By multivariate analysis, secondary anthracycline-resistant disease was significantly associated (P &lt; .05) with lower ORR and shorter TTF and OS, whereas anthracycline-refractory disease was associated with shorter OS. Poor performance status was associated with lower ORR, shorter TTF, and shorter OS. Liver dysfunction (transaminase levels &gt; 1.5 times the upper limit of normal [ULN] and alkaline phosphatase [AP] level &gt; three times ULN) and time since first relapse less than 24 months were associated with shorter TTF and OS. Other significant correlations included the following: elevated CA 15-3 serum level with lower ORR; more than two involved sites, and minor transaminase and AP level abnormalities with shorter OS; and no previous chemotherapy for ABC with shorter TTF. According to multivariate analysis, ORR, TTF, and OS were not decreased in patients with liver metastases but without liver dysfunction. <\/jats:p><jats:p> CONCLUSION: Docetaxel activity was maintained in heavily pretreated ABC patients and in those with liver metastasis; docetaxel must be used cautiously, however, in patients with liver dysfunction in whom high morbidity risk necessitates strict adherence to dose-adaptation guidelines. <\/jats:p>","DOI":"10.1200\/jco.2000.18.3.562","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T07:04:24Z","timestamp":1487919864000},"page":"562-562","source":"Crossref","is-referenced-by-count":69,"title":["Factors Predicting for Efficacy and Safety of Docetaxel in a Compassionate-Use Cohort of 825 Heavily Pretreated Advanced Breast Cancer Patients"],"prefix":"10.1200","volume":"18","author":[{"given":"J.","family":"Alexandre","sequence":"first","affiliation":[{"name":"From the Paul Brousse Hospital and Institut Gustave RoussyVillejuif; Cvitkovic & Associ\u00e9s Consultants, Kremlin-Bic\u00eatre; Centre Oscar Lambret, Lille; Saint Louis Hospital, Paris; Centre L\u00e9on B\u00e9rard, Lyon; Centre Paoli Calmettes, Marseille; and Roger Bellon and Rh\u00f4ne-Poulenc Rorer, Montrouge, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bleuzen","sequence":"additional","affiliation":[{"name":"From the Paul Brousse Hospital and Institut Gustave RoussyVillejuif; Cvitkovic & Associ\u00e9s Consultants, Kremlin-Bic\u00eatre; Centre Oscar Lambret, Lille; Saint Louis Hospital, Paris; Centre L\u00e9on B\u00e9rard, Lyon; Centre Paoli Calmettes, Marseille; and Roger Bellon and Rh\u00f4ne-Poulenc Rorer, Montrouge, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bonneterre","sequence":"additional","affiliation":[{"name":"From the Paul Brousse Hospital and Institut Gustave RoussyVillejuif; Cvitkovic & Associ\u00e9s Consultants, Kremlin-Bic\u00eatre; Centre Oscar Lambret, Lille; Saint Louis Hospital, Paris; Centre L\u00e9on B\u00e9rard, Lyon; Centre Paoli Calmettes, Marseille; and Roger Bellon and Rh\u00f4ne-Poulenc Rorer, Montrouge, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Sutherland","sequence":"additional","affiliation":[{"name":"From the Paul Brousse Hospital and Institut Gustave RoussyVillejuif; Cvitkovic & Associ\u00e9s Consultants, Kremlin-Bic\u00eatre; Centre Oscar Lambret, Lille; Saint Louis Hospital, Paris; Centre L\u00e9on B\u00e9rard, Lyon; Centre Paoli Calmettes, Marseille; and Roger Bellon and Rh\u00f4ne-Poulenc Rorer, Montrouge, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Misset","sequence":"additional","affiliation":[{"name":"From the Paul Brousse Hospital and Institut Gustave RoussyVillejuif; Cvitkovic & Associ\u00e9s Consultants, Kremlin-Bic\u00eatre; Centre Oscar Lambret, Lille; Saint Louis Hospital, Paris; Centre L\u00e9on B\u00e9rard, Lyon; Centre Paoli Calmettes, Marseille; and Roger Bellon and Rh\u00f4ne-Poulenc Rorer, Montrouge, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-P.","family":"Guastalla","sequence":"additional","affiliation":[{"name":"From the Paul Brousse Hospital and Institut Gustave RoussyVillejuif; Cvitkovic & Associ\u00e9s Consultants, Kremlin-Bic\u00eatre; Centre Oscar Lambret, Lille; Saint Louis Hospital, Paris; Centre L\u00e9on B\u00e9rard, Lyon; Centre Paoli Calmettes, Marseille; and Roger Bellon and Rh\u00f4ne-Poulenc Rorer, Montrouge, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Viens","sequence":"additional","affiliation":[{"name":"From the Paul Brousse Hospital and Institut Gustave RoussyVillejuif; Cvitkovic & Associ\u00e9s Consultants, Kremlin-Bic\u00eatre; Centre Oscar Lambret, Lille; Saint Louis Hospital, Paris; Centre L\u00e9on B\u00e9rard, Lyon; Centre Paoli Calmettes, Marseille; and Roger Bellon and Rh\u00f4ne-Poulenc Rorer, Montrouge, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Faivre","sequence":"additional","affiliation":[{"name":"From the Paul Brousse Hospital and Institut Gustave RoussyVillejuif; Cvitkovic & Associ\u00e9s Consultants, Kremlin-Bic\u00eatre; Centre Oscar Lambret, Lille; Saint Louis Hospital, Paris; Centre L\u00e9on B\u00e9rard, Lyon; Centre Paoli Calmettes, Marseille; and Roger Bellon and Rh\u00f4ne-Poulenc Rorer, Montrouge, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Chahine","sequence":"additional","affiliation":[{"name":"From the Paul Brousse Hospital and Institut Gustave RoussyVillejuif; Cvitkovic & Associ\u00e9s Consultants, Kremlin-Bic\u00eatre; Centre Oscar Lambret, Lille; Saint Louis Hospital, Paris; Centre L\u00e9on B\u00e9rard, Lyon; Centre Paoli Calmettes, Marseille; and Roger Bellon and Rh\u00f4ne-Poulenc Rorer, Montrouge, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Spielman","sequence":"additional","affiliation":[{"name":"From the Paul Brousse Hospital and Institut Gustave RoussyVillejuif; Cvitkovic & Associ\u00e9s Consultants, Kremlin-Bic\u00eatre; Centre Oscar Lambret, Lille; Saint Louis Hospital, Paris; Centre L\u00e9on B\u00e9rard, Lyon; Centre Paoli Calmettes, Marseille; and Roger Bellon and Rh\u00f4ne-Poulenc Rorer, Montrouge, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bensma\u00efne","sequence":"additional","affiliation":[{"name":"From the Paul Brousse Hospital and Institut Gustave RoussyVillejuif; Cvitkovic & Associ\u00e9s Consultants, Kremlin-Bic\u00eatre; Centre Oscar Lambret, Lille; Saint Louis Hospital, Paris; Centre L\u00e9on B\u00e9rard, Lyon; Centre Paoli Calmettes, Marseille; and Roger Bellon and Rh\u00f4ne-Poulenc Rorer, Montrouge, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Marty","sequence":"additional","affiliation":[{"name":"From the Paul Brousse Hospital and Institut Gustave RoussyVillejuif; Cvitkovic & Associ\u00e9s Consultants, Kremlin-Bic\u00eatre; Centre Oscar Lambret, Lille; Saint Louis Hospital, Paris; Centre L\u00e9on B\u00e9rard, Lyon; Centre Paoli Calmettes, Marseille; and Roger Bellon and Rh\u00f4ne-Poulenc Rorer, Montrouge, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mahjoubi","sequence":"additional","affiliation":[{"name":"From the Paul Brousse Hospital and Institut Gustave RoussyVillejuif; Cvitkovic & Associ\u00e9s Consultants, Kremlin-Bic\u00eatre; Centre Oscar Lambret, Lille; Saint Louis Hospital, Paris; Centre L\u00e9on B\u00e9rard, Lyon; Centre Paoli Calmettes, Marseille; and Roger Bellon and Rh\u00f4ne-Poulenc Rorer, Montrouge, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Cvitkovic","sequence":"additional","affiliation":[{"name":"From the Paul Brousse Hospital and Institut Gustave RoussyVillejuif; Cvitkovic & Associ\u00e9s Consultants, Kremlin-Bic\u00eatre; Centre Oscar Lambret, Lille; Saint Louis Hospital, Paris; Centre L\u00e9on B\u00e9rard, Lyon; Centre Paoli Calmettes, Marseille; and Roger Bellon and Rh\u00f4ne-Poulenc Rorer, Montrouge, France."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R2-0069","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.124"},{"key":"R3-0069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.8.2197"},{"key":"R4-0069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.7.2401"},{"key":"R5-0069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.8.2043"},{"key":"R6-0069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.6.1453"},{"key":"R7-0069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.764"},{"key":"R8-0069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.2.305"},{"key":"R9-0069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.5.560"},{"key":"R10-0069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.7.1245"},{"key":"R11-0069","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058873"},{"key":"R12-0069","unstructured":"Gianni  L:  Anthracycline resistance:  The problem and its current definition. Semin Oncol 24:S11,1997\u2013S17,   (suppl 10)"},{"key":"R13-0069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.2.314"},{"key":"R14-0069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.58"},{"key":"R15-0069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.12.2879"},{"key":"R16-0069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.2.422"},{"key":"R17-0069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.12.2886"},{"key":"R18-0069","doi-asserted-by":"publisher","DOI":"10.1016\/0964-1955(95)00007-5"},{"key":"R19-0069","unstructured":"Riva  A,  Fumoleau  P,  Roche  H, et al:  Efficacy and safety of different corticosteroid premedications in breast cancer patients treated with Taxotere.  Proc Am Soc Clin Oncol 16:188a,1997  (abstr 660)"},{"key":"R20-0069","unstructured":"Bruno  R,  Sanderink  GJ:  Pharmacokinetics and metabolism of Taxotere (docetaxel).  Cancer Surv 17:305,1993-313,"},{"key":"R21-0069","doi-asserted-by":"publisher","DOI":"10.1007\/BF02353487"},{"key":"R22-0069","unstructured":"Klink-Alakl  M,  Riva  A,  Bruno  R, et al:  Taxotere safety profile in patients with liver metastases with or without impaired liver function.  Proc Am Soc Clin Oncol 16:220a,1997  (abstr 770)"},{"key":"R23-0069","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(99)00174-4"},{"key":"R24-0069","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"R26-0069","doi-asserted-by":"crossref","unstructured":"Cox  DR:  Regression models and life-tables (with discussion).  J R Stat Soc [B] 34:187,1972-220,","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"R27-0069","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19891015)64:8<1674::AID-CNCR2820640820>3.0.CO;2-V"},{"key":"R28-0069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.187"},{"key":"R29-0069","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)00340-7"},{"key":"R30-0069","unstructured":"Vermorken  JB,  ten Bokkel Huinink  WW,  Mandjes  IAM, et al:  High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy:  A European Cancer Center Trial. Semin Oncol 22:16,1995-22,   (suppl 8)"},{"key":"R31-0069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.5.1152"},{"key":"R32-0069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.8.1621"},{"key":"R33-0069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.8.2056"},{"key":"R34-0069","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008370930599"},{"key":"R35-0069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3362"},{"key":"R36-0069","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008290406221"},{"key":"R37-0069","unstructured":"Chan  S,  Friedrichs  K,  No\u00ebl  D, et al:  A randomized phase III study of Taxotere (T) versus doxorubicin (D) in patients (pts) with metastatic breast cancer (MBC) who have failed an alkylating containing regimen:  Preliminary results. Proc Am Soc Clin Oncol 16:154a,1997  (abstr 540)"},{"key":"R38-0069","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(96)00446-7"},{"key":"R39-0069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.1.55"},{"key":"R40-0069","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920701)70:1<129::AID-CNCR2820700122>3.0.CO;2-Y"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2000.18.3.562","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:38:51Z","timestamp":1653514731000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2000.18.3.562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2,1]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,2,1]]}},"alternative-id":["10.1200\/JCO.2000.18.3.562"],"URL":"https:\/\/doi.org\/10.1200\/jco.2000.18.3.562","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,2,1]]}}}